Crinetics Pharmaceuticals, Inc.
CRNX
Classement en actions
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Prix de l'action
$84.95
Dernière synchronisation: 2026-09-01
Capitalisation boursière
$9.00B
Changement (1 jour)
0.00%
Changement (1 an)
98.25%
Pays
US
Échange Crinetics Pharmaceuticals, Inc. (CRNX)
Catégorie
Healthcare
Bénéfices pour Crinetics Pharmaceuticals, Inc. (CRNX)
Bénéfices en Jun 2026 TTM : $-501.43M
Selon les derniers rapports financiers de Crinetics Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de $-501.43M. En 2023, l'entreprise a réalisé un bénéfice de $-214.53M, une diminution par rapport à celui de 2022 qui était de $-163.92M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Crinetics Pharmaceuticals, Inc. de 2016 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -489.02% |
NL
|
